GSA Capital Partners’s ProQR Therapeutics PRQR Stock Holding History

GSA Capital Partners’s Portfolio PRQR Stock Details PRQR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$185K	Buy	+114,256	New	+$187K	0.01%	1474
2025 Q2	–	Sell	-14,683	Closed	-$20K	–	2071
2025 Q1	$20K	Buy	+14,683	New	+$31.3K	﹤0.01%	1585
2023 Q4	–	Sell	-74,084	Closed	-$96K	–	1837
2023 Q3	$96K	Buy	74,084 +30,248	+69%	+$47.6K	0.01%	1392
2023 Q2	$71K	Buy	+43,836	New	+$85.6K	0.01%	1402
2023 Q1	–	Sell	-21,514	Closed	-$80K	–	1846
2022 Q4	$80K	Buy	+21,514	New	+$28.2K	0.01%	1329
2021 Q4	–	Sell	-137,003	Closed	-$1.15M	–	1719
2021 Q3	$1.15M	Buy	137,003 +75,714	+124%	+$495K	0.12%	239
2021 Q2	$413K	Buy	61,289 +35,137	+134%	+$227K	0.05%	753
2021 Q1	$173K	Sell	26,152 -21,473	-45%	-$110K	0.03%	936
2020 Q4	$200K	Buy	+47,625	New	+$201K	0.03%	994
2019 Q4	–	Sell	-11,231	Closed	-$65K	–	1667
2019 Q3	$65K	Buy	+11,231	New	+$89.7K	0.01%	1304

Other funds holding PRQR

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

PFM

Privium Fund Management Amsterdam, Netherlands $480M AUM 77.45% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

PIM

Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return

GSA Capital Partners's PRQR Position: Q1 2026 in Review

GSA Capital Partners opened a new position in ProQR Therapeutics (PRQR) in Q1 2026: 114,256 shares worth $185K. The stake represents 0.01% of the portfolio and ranks #1474 among its holdings. This is a return to the name: GSA Capital Partners previously reported a position in PRQR as recently as Q1 2025.

GSA Capital Partners first reported a position in PRQR in Q3 2019 and has held it in 10 quarters since. The position peaked at $1.15M in Q3 2021. 69 funds tracked by Wall St. Rank hold PRQR as of Q1 2026.

GSA Capital Partners held 114,256 shares of ProQR Therapeutics worth $185K as of Q1 2026.
ProQR Therapeutics was a new GSA Capital Partners position in Q1 2026.
ProQR Therapeutics made up 0.01% of GSA Capital Partners's portfolio in Q1 2026, its #1474 holding.
GSA Capital Partners first reported a position in ProQR Therapeutics in Q3 2019 and has held it in 10 quarters since.
GSA Capital Partners's ProQR Therapeutics position peaked at $1.15M in Q3 2021.
69 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q1 2026.

Based on GSA Capital Partners's 13F filing for Q1 2026, filed 8 May 2026.